The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin

Alessandra Mangia, Andrea Arleo, Massimiliano Copetti, Maria Miscio, Valeria Piazzolla, Rosanna Santoro, Maria Maddalena Squillante

Research output: Contribution to journalArticle

Abstract

Background: The current standard-of-care for treatment of HCV genotype 2 (GT-2) patients is the combination of sofosbuvir (SOF) with weight-based ribavirin (RBV). Patients with HCV GT-2 infection and ribavirin contraindications require the use of SOF plus NS5A inhibitor daclatasvir (DCV) which is not reimbursed everywhere. Methods: We conducted an open-label observational, prospective study on a subgroup of GT-2 patients either naïve or treatment experienced (TE) with contraindications to the use of RBV. Patients with cirrhosis of Child–Pugh–Turcotte (CPT) class A and B or advanced fibrosis with comorbidities were included. They were assigned to receive 12 or 24 weeks of SOF/DCV. The primary end point of the study was sustained virological response (SVR) defined as HCV RNA levels

Original languageEnglish
Pages (from-to)971-976
Number of pages6
JournalLiver International
Volume36
Issue number7
DOIs
Publication statusPublished - Jul 1 2016

Keywords

  • daclatasvir
  • genotype-2
  • ribavirin free
  • sofosbuvir

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin'. Together they form a unique fingerprint.

  • Cite this